Revue medicale suisse最新文献

In this article, we look at a selection of recent developments in various areas of endocrinology. We focus on advances in endocrine pharmacotherapy and endocrine surgery, addressing several areas: a) the thyroid safety of Glucagon-Like Peptide-1 (GLP1) analogues; b) the efficacy of adrenal surgery for mild autonomous cortisol secretion; c) crinecerfont in the management of congenital adrenal hyperplasia in adults and children; d) paltusotin as a novel oral therapy for acromegaly and e) TransCon PTH (palopegteriparatide) as a novel therapy for chronic hypoparathyroidism.

Parkinson's disease affects around 6 million people worldwide. It causes both motor and non-motor symptoms. Since there is no cure, medical treatment aims to improve patients' quality of life. Combined with drug treatment, neurorehabilitation plays a major role in this field, thanks to its multidisciplinary approach. Practices such as physical therapy, Tai Chi, dance, and music therapy have shown positive results throughout the course of the disease. In addition, innovations such as augmented reality or specific treadmill training have interesting potential. However, further research is needed to refine therapeutic strategies and optimize the effectiveness of treatments.

Patients with serious illnesses wish to maintain their autonomy and decide the course of their end of life. The role of healthcare professionals is to assess the patient's understanding of their illness, help them become aware of the progression of their condition, and adapt these conversations according to the patient's emotional state, while providing regular spaces for discussion. Some patients continue to have expectations that may seem unrealistic despite a limited prognosis. The goal is to align treatments with the patient's ' objectives and values, while guiding them toward existential maturation, which represents the necessary process of accepting one's own mortality as a non-traumatic event. This process is built through repeated interactions with the patient, which is why it is crucial to begin these discussions early.

Trust is a particularly important element in a healthcare relationship, but it is often misunderstood. In this article, we explore the trust relationship between patients and healthcare professionals and the expectations underpinning it. We then look at some of the expectations of trans* people in the context of medical consultations that are not related to medical transition. In this article, we present lines of thought from a qualitative research currently being analyzed and conducted by Iris Rivoire, Dr. Mira Fey, and Prof. Samia Hurst-Majno.

This article highlights recent advancements in otorhinolaryngology. It reviews innovations in managing sudden sensory-neural hearing loss through low-dose glucocorticoid treatments and explores pediatric audiology breakthroughs, particularly gene therapy for DFNB9 deafness. In speech pathology and oncology, a new minimally invasive robotic surgical approach enhances organ preservation for head and neck cancers. Rhinology advancements include biological therapies for chronic rhinosinusitis with polyps. Together, these developments expand therapeutic options, significantly improving patient quality of life in the ORL field.

Certain molecules, such as GLP-1 agonists and endothelin antagonists, possess nephroprotective properties. When treating IgA nephropathy, endothelin antagonists and sibeprenlimab have shown effectiveness in slowing the progression of chronic kidney isease. Additionally, the infusion of amino acids can reduce the incidence of mild acute kidney injury following cardiac surgery. In hemodialysis, the sodium content in the dialysate appears to affect patient mortality rates. For individuals starting hemodialysis after the age of 75, there is a modest survival benefit, although it comes at the cost of reduced time spent at home. In the future, noninvasive biomarkers may enable early detection of renal graft rejection.

New therapeutic agents in oncology are emerging rapidly, both in terms of the number of approved drugs and the technological and biological innovation of new treatments. Antibody-drug conjugates (ADC) offer a promising cancer therapy by specifically targeting tumor cells. ADC are composed of a monoclonal antibody recognizing the tumor cell via specific antigens, coupled with a potent cytotoxic agent that resembles classical chemotherapy. This mechanism of action aims to deliver the cytotoxic agent directly to the tumor cell and spare healthy cells. However, important toxicities have been reported. On the one hand, these toxicities are related to the cytotoxic agents that, once delivered locally, spread to other parts of the body. On the other hand, there are specific toxicities associated with these ADC, which we address in this article.